帕瓦股份(688184) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -1,345 million and -900 million CNY, a decrease of 124,763 million to 80,263 million CNY compared to the previous year, representing a year-on-year decline of 1,281.33% to 824.31%[3] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is projected to be between -1,340 million and -895 million CNY, a decrease of 124,024.71 million to 79,524.71 million CNY compared to the previous year, reflecting a year-on-year decline of 1,243.32% to 797.22%[5] - In 2023, the company reported a total profit of -120.39 million CNY and a net profit attributable to shareholders of -97.37 million CNY[6] Sales and Production - The company achieved sales of approximately 18,900 tons of positive electrode precursor products, an increase of 27.10% compared to 2023[8] Factors Affecting Performance - The decline in performance is attributed to market environment changes, intensified industry competition, raw material price fluctuations, and increased unit costs due to fixed asset depreciation[8] - The company has made provisions for impairment on certain inventories, fixed assets, and accounts receivable, significantly impacting current profits[8] Research and Development - The company has increased R&D investment in new products, technologies, and processes to maintain its technological advantage[8] Audit and Investment Risks - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by registered accountants[9] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[10]